Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Wumeiwan Jiawei Fang is a modified Traditional Chinese Medicine (TCM) formula derived from the classical Wumeiwan (Mume Pill), which originated in the *Shanghan Lun*. This specific modification is being evaluated by the China Academy of Chinese Medical Sciences for its efficacy and safety in treating idiopathic blepharospasm, a condition characterized by involuntary eyelid closure. The base formula, Wumeiwan, traditionally comprises ten herbs including Mume Fructus, Coptidis Rhizoma, and Aconiti Lateralis Radix Praeparata, and is used in TCM to address complex patterns of heat and cold. The "Jiawei" (added flavors) aspect indicates the inclusion of additional medicinal herbs intended to enhance the formula's ability to extinguish "internal wind" and relax muscle spasms, aligning with TCM therapeutic principles for movement disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on wumeiwan jiawei fang.